Development of 131I-tositumomab.

@article{Lewington2005DevelopmentO1,
  title={Development of 131I-tositumomab.},
  author={Valerie J. Lewington},
  journal={Seminars in oncology},
  year={2005},
  volume={32 1 Suppl 1},
  pages={S50-6}
}
The median survival for patients with advanced indolent non-Hodgkin's lymphoma (NHL) has remained at 7 to 8 years since the 1960s. Targeted treatment using radioimmunotherapy (RIT), radiolabeled monoclonal antibodies directed against tumor-specific antigens, is an attractive option for this patient population, combining the advantages of an active biologic therapy with low dose-rate irradiation of an inherently radiosensitive tumor. Two anti-CD20 RIT agents have now been approved for the… CONTINUE READING